HC Wainwright Issues Negative Estimate for Ardelyx Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Ardelyx in a note issued to investors on Friday, August 7th. HC Wainwright analyst M. Caufield now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their prior forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.10) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.26) EPS and FY2030 earnings at $1.61 EPS.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The business had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. The business’s revenue was up 34.3% compared to the same quarter last year.

ARDX has been the subject of a number of other reports. TD Cowen cut their target price on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. LADENBURG THALM/SH SH started coverage on shares of Ardelyx in a report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 target price for the company. Weiss Ratings cut Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. BTIG Research cut their target price on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Citigroup decreased their price objective on Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Ardelyx Price Performance

ARDX stock opened at $4.00 on Tuesday. Ardelyx has a 12 month low of $3.90 and a 12 month high of $8.40. The company has a current ratio of 3.49, a quick ratio of 3.28 and a debt-to-equity ratio of 1.37. The company has a market cap of $996.75 million, a price-to-earnings ratio of -18.18 and a beta of 0.70. The firm has a 50-day moving average of $5.34 and a two-hundred day moving average of $6.04.

Insider Activity at Ardelyx

In other Ardelyx news, insider Eric Duane Foster sold 7,998 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total value of $50,147.46. Following the transaction, the insider directly owned 417,972 shares in the company, valued at $2,620,684.44. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mike Kelliher sold 7,248 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $45,444.96. Following the sale, the insider directly owned 357,418 shares in the company, valued at approximately $2,241,010.86. The trade was a 1.99% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 24,572 shares of company stock valued at $154,066. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ARDX. BlackRock Inc. acquired a new stake in Ardelyx during the 2nd quarter worth $119,874,000. AIGH Capital Management LLC acquired a new position in Ardelyx in the second quarter valued at $16,320,000. Bank of America Corp DE grew its holdings in shares of Ardelyx by 88.8% during the second quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company’s stock worth $21,670,000 after purchasing an additional 2,600,080 shares during the last quarter. State Street Corp grew its holdings in shares of Ardelyx by 22.6% during the fourth quarter. State Street Corp now owns 11,912,339 shares of the biopharmaceutical company’s stock worth $69,449,000 after purchasing an additional 2,193,649 shares during the last quarter. Finally, Rubric Capital Management LP purchased a new position in shares of Ardelyx during the first quarter worth about $11,147,000. 58.92% of the stock is owned by hedge funds and other institutional investors.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.